BBIO - BridgeBio Pharma Inc
IEX Last Trade
27.86
3.240 11.630%
Share volume: 9,110,089
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$24.62
3.24
13.16%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-03 | 2023-02-23 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-02-22 | 2024-05-02 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 728.740 M | 623.036 M | 625.680 M | 503.661 M | 655.008 M | 546.380 M | 849.333 M | 794.375 M | |
| Current Assets | 642.219 M | 548.853 M | 552.702 M | 432.884 M | 587.670 M | 477.593 M | 783.424 M | 616.236 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 50.242 M | 39.001 M | 35.906 M | 29.160 M | 27.753 M | 26.056 M | 263.602 M | 29.056 M | |
| Short Term Investments | 50.242 M | 39.001 M | 35.906 M | 29.160 M | 27.753 M | 26.056 M | 263.602 M | 29.056 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 591.977 M | 471.922 M | 491.293 M | 383.794 M | 543.265 M | 434.884 M | 519.691 M | 447.771 M | |
| Total Non-current Assets | 86.521 M | 74.183 M | 72.978 M | 70.777 M | 67.338 M | 68.787 M | 65.909 M | 178.139 M | |
| Property Plant Equipment | 15.603 M | 14.569 M | 13.566 M | 13.047 M | 12.413 M | 11.816 M | 11.414 M | 9.840 M | |
| Other Assets | 29.870 M | 20.224 M | 20.767 M | 20.401 M | 18.676 M | 22.625 M | 20.722 M | 18.903 M | |
| Intangible Assets | 29.310 M | 28.712 M | 28.113 M | 27.515 M | 26.917 M | 26.319 M | 25.721 M | 25.123 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 728.740 M | 623.036 M | 625.680 M | 503.661 M | 655.008 M | 546.380 M | 849.333 M | 794.375 M | |
| Total liabilities | 1.867 B | 1.878 B | 1.851 B | 1.866 B | 1.863 B | 1.901 B | 1.899 B | 1.887 B | |
| Total current liabilities | 119.194 M | 121.428 M | 96.596 M | 110.120 M | 106.065 M | 143.844 M | 141.477 M | 134.364 M | |
| Accounts Payable | 10.158 M | 11.558 M | 4.076 M | 3.874 M | 4.472 M | 10.655 M | 4.728 M | 18.126 M | |
| Other liabilities | 28.226 M | 26.643 M | 17.501 M | 13.326 M | 11.785 M | 9.361 M | 20.485 M | 17.446 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 1.699 B | 1.708 B | 1.713 B | 1.719 B | 1.721 B | 1.727 B | 1.716 B | 1.718 B | |
| Other liabilities | 28.226 M | 26.643 M | 17.501 M | 13.326 M | 11.785 M | 9.361 M | 20.485 M | 17.446 M | |
| Minority interest | 8.044 M | 9.693 M | 12.052 M | 12.385 M | 13.808 M | 11.722 M | 12.670 M | 10.832 M | |
| Total Shareholder equity | -1.138 B | -1.255 B | -1.226 B | -1.362 B | -1.208 B | -1.354 B | -1.050 B | -1.093 B | |
| Common stock | 147.938 M | 149.388 M | 152.646 M | 160.535 M | 163.309 M | 174.676 M | 178.705 M | 187.587 M | |
| Retained earnings | -1.781 B | -1.918 B | -2.057 B | -2.215 B | -2.392 B | -2.561 B | -2.596 B | -2.669 B |